Lilly Beats And Raises

Eli Lilly beat profit estimates and raised guidance. Pfizer did the same yesterday but the stock fell flat. I believe Eli Lilly has a better chance of rallying even though it has already had a nice run, as it is the most hated pharmaceutical stock. Goldman Sachs has it on its Conviction Sell List. When a stock is hated and does well, there is a lot of upside potential. Eli Lilly is my second largest holding, next to Pfizer.


Anonymous said...

LLY beats expectations, yet is down 40 cents... gotta love it.

Anonymous said...

Gilead beat expectations and is down 3.6%. Apparently investors are concerned about patent expirations that take place from 2017 to 2021. Somehow the distant future doesn't worry anyone where Wells Fargo or Apple are concerned.